Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

• Main Authors: Ying Zhu (Author), Kun-Bin Ke (Author), Zhong-Kun Xia (Author), Hong-Jian Li (Author), Rong Su (Author), Chao Dong (Author), Feng-Mei Zhou (Author), Lin Wang (Author), Rong Chen (Author), Shi-Guo Wu (Author), Hui Zhao (Author), Peng Gu (Author), Kwong-Sak Leung (Author), Man-Hon Wong (Author), Gang Lu (Author), Jian-Ying Zhang (Author), Bing-Hua Jiang (Author), Jian-Ge Qiu (Author), Xi-Nan Shi (Author), Marie Chia-mi Lin (Author)
• Format: Book
• Published: BMC, 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Cyclin-dependent kinases 2/4/6 (CDK2/4/6) play critical roles in cell cycle progression, and their deregulations are hallmarks of hepatocellular carcinoma (HCC). Methods We used the combination of computational and experimental approaches to discover a CDK2/4/6 triple-inhibitor f...